RxDoctor Payments DataLook up a doctor →

Gary Crump, MD

Rheumatology · Louisville, KYNPI 1285709386

Payments from drug & device makers

$175,691in general payments, 2019–2025

Across 1,483 payments — averaging $118.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$91K
  • AbbVie$31K
  • Novartis$25K
  • UCB, Inc.$16K
  • Johnson & Johnson$4K
  • AstraZeneca$1K
  • plus $8K from 28 others

What the payments were for

  • Consulting fees$20,64112%
  • Speaking & faculty fees$106,74461%
  • Travel & lodging$14,6428%
  • Food & beverage$33,23519%
  • Education$4300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$175,691 in reported general payments places this provider in the 85th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,786,899
Medicare patients
502
Services billed
227,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib44$329,904
Humira(Cf) PenAdalimumab21$244,192
Humira PenAdalimumab21$165,087
Orencia ClickjectAbatacept21$161,327
Enbrel SureclickEtanercept14$159,537
Enbrel MiniEtanercept12$89,022
MethotrexateMethotrexate Sodium278$7,654
Hydroxychloroquine Sulfate220$7,158
Pilocarpine Hcl44$4,880
Celecoxib107$2,970
Colchicine50$2,857
Cevimeline Hcl13$2,521
Leflunomide53$1,836
Febuxostat47$1,702
Allopurinol159$1,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$31,195$329,90444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →